masitinib Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumours in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. Masitinib has been studied for several human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer, Alzheimer disease, multiple sclerosis, rheumatoid arthritis, mastocytosis, amyotrophic lateral sclerosis and COVID-19.   Wikipedia

Chemistry

  • SMILES: CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nc(cs4)c5cccnc5)c3)CC1
  • InChIKey: WJEOLQLKVOPQFV-UHFFFAOYSA-N
  • Mol. Mass: 498.66
  • ALogP: 5.26
  • ChEMBL Molecule:
    masitinib  
More Chemistry

Pharmacology

Alternative names

4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide | ab1010 | ab 1010 | ab-1010 | kinavet ca-1 | masatinib | masican | masitinib | masitinib mesilate | masitinib mesylate | masivet

Organizations (15)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Alzheimer Disease (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Asthma (Phase 3)

Colorectal Neoplasms (Phase 3)

COVID-19 (Phase 2)

Gastrointestinal Stromal Tumors (Phase 3)

Intestinal Neoplasms (Phase 3)

Mastocytosis (Phase 2)

Mastocytosis, Systemic (Phase 3)

Melanoma (Phase 3)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 2/Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 3)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 39
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue